"The findings suggest that epigenetic changes may mediate the link between arsenic exposure and adverse health outcomes."
New Biomarker for Arsenic Exposure Developed from Epigenetic Changes
The Study
Researchers at the University of Chicago conducted a study analyzing blood samples from over 1,100 adults in Bangladesh, a region with high arsenic contamination in well water. Using DNA methylation arrays, they scanned more than 700,000 genomic sites and identified 1,177 sites significantly associated with arsenic exposure, most of which were previously unknown.
Key Findings
- Mendelian randomization analysis indicated that arsenic metabolism likely causes changes in DNA methylation at these sites.
- The researchers developed a biomarker from 255 of these sites that predicts urinary arsenic levels, arsenical skin lesions, and overall mortality.
- The biomarker was validated in a U.S. population with lower arsenic exposure, showing predictive ability though with reduced precision.
Overlap with Chronic Disease
Many of the identified genomic sites overlap with regions previously linked to chronic diseases such as heart disease, type 2 diabetes, and various cancers.
Significance
The study provides a DNA methylation-based biomarker for arsenic exposure assessment, which may be more stable than direct urinary measurements due to arsenic's short half-life. The findings suggest that epigenetic changes may mediate the link between arsenic exposure and adverse health outcomes.